^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSH2 mutation

    i
    Other names: MSH2, MutS Homolog 2, HMSH2, MutS (E. Coli) Homolog 2, MutS Homolog 2, Nonpolyposis Type 1, DNA Mismatch Repair Protein Msh2, MutS Protein Homolog 2, HNPCC1, HNPCC, LCFS2, COCA1, FCC1
    Entrez ID:
    4436
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes (NCT02371135)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/01/2015
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Researching the Effect of Aerobic Exercise on Cancer (NCT03996239)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/20/2019
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Atorvastatin ± Aspirin in Lynch Syndrome Syndrome (NCT04379999)
    Phase 1
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    09/10/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MLH1 • MSH6 • MSH2 • EPCAM • CASP3
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    atorvastatin
    Pancreatic Cancer Early Detection Program (PCEDP) (NCT02206360)
    Phase N/A
    White Plains Hospital
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2024
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals (NCT03250078)
    Phase N/A
    Nuvance Health
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    11/01/2016
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation
    A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome (NCT05411718)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/21/2023
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    aspirin
    GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study (NCT03751761)
    Phase 1/2
    Asan Medical Center
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    06/11/2018
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation
    |
    Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)
    Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention (NCT05677048)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    04/14/2023
    Primary completion :
    10/31/2025
    Completion :
    10/31/2027
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM
    |
    BRCA1 mutation • MSH2 mutation • PMS2 mutation
    Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study (NCT05410977)
    Phase N/A
    Mayo Clinic
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    03/30/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome (NCT03495674)
    Phase N/A
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/05/2024
    Initiation :
    04/04/2018
    Primary completion :
    01/02/2024
    Completion :
    01/02/2024
    MSI • MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    GENetic Education Risk Assessment and TEsting Study (GENERATE) (NCT03762590)
    Phase N/A
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    12/20/2023
    Initiation :
    05/08/2019
    Primary completion :
    12/12/2022
    Completion :
    12/31/2027
    TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM
    |
    TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation
    Cohort Study of Pancreatic Cancer Risk (NCT04247503)
    Phase N/A
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    08/01/2023
    Initiation :
    12/11/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM
    |
    TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation
    CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome (CADLYNCH) (NCT05963191)
    Phase N/A
    PERROD Guillaume
    Not yet recruiting
    Last update posted :
    07/27/2023
    Initiation :
    10/02/2023
    Primary completion :
    10/02/2023
    Completion :
    10/02/2025
    MSH2
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Validation of an AI-based Biliopancreatic EUS Navigation System for Real-time Quality Improvement: A Prospective, Single-center, Randomized Controlled Trial (NCT05457101)
    Phase N/A
    Renmin Hospital of Wuhan University
    Recruiting
    Last update posted :
    06/22/2023
    Initiation :
    07/01/2022
    Primary completion :
    07/01/2023
    Completion :
    07/30/2023
    BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM
    |
    BRCA1 mutation • STK11 mutation • PALB2 mutation • MSH2 mutation • PMS2 mutation
    Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    09/12/2022
    Initiation :
    01/28/2021
    Primary completion :
    06/21/2022
    Completion :
    06/21/2022
    TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3
    |
    MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (MesaCAPP) (NCT04920149)
    Phase 2
    Ann-Sofie Backman
    Recruiting
    Last update posted :
    03/28/2022
    Initiation :
    03/21/2022
    Primary completion :
    10/15/2028
    Completion :
    10/15/2038
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation
    the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer (NCT05131243)
    Phase N/A
    Fujian Cancer Hospital
    Not yet recruiting
    Last update posted :
    11/23/2021
    Initiation :
    12/01/2021
    Primary completion :
    05/01/2023
    Completion :
    05/01/2023
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation
    Naproxen for Lynch Syndrome (NCT02048735)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    12/12/2017
    Initiation :
    01/01/2014
    Primary completion :
    01/01/2021
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Prostate Cancer Screening Among Men With High Risk Genetic Predisposition (NCT02053805)
    Phase N/A
    Rabin Medical Center
    Unknown status
    Last update posted :
    10/17/2017
    Initiation :
    02/01/2014
    Primary completion :
    06/01/2018
    Completion :
    06/01/2019
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
    The GEOLynch Cohort Study (NCT03303833)
    Phase N/A
    Wageningen University
    Recruiting
    Last update posted :
    10/06/2017
    Initiation :
    07/01/2006
    Primary completion :
    12/01/2030
    Completion :
    12/01/2030
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (NCT02864979)
    Phase 2
    Rabin Medical Center
    Not yet recruiting
    Last update posted :
    09/20/2017
    Initiation :
    08/01/2016
    Primary completion :
    07/01/2022
    Completion :
    07/01/2022
    MLH1 • MSH6 • MSH2
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    I-Scan For Colon Polyp Detection In HNPCC (NCT01823471)
    Phase N/A
    Universitaire Ziekenhuizen Leuven
    Completed
    Last update posted :
    07/26/2017
    Initiation :
    11/01/2010
    Primary completion :
    06/01/2013
    Completion :
    06/01/2013
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation
    Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer (NCT00341575)
    Phase N/A
    National Human Genome Research Institute (NHGRI)
    Completed
    Last update posted :
    07/02/2017
    Initiation :
    09/28/2005
    Completion :
    08/02/2010
    MSH2
    |
    MSH2 mutation • MLH1 mutation
    Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome (ChromoLynch) (NCT00905710)
    Phase N/A
    University Medical Center Groningen
    Completed
    Last update posted :
    05/13/2016
    Initiation :
    09/01/2008
    Primary completion :
    05/01/2016
    Completion :
    05/01/2016
    MLH1 • MSH6 • MSH2
    |
    MSH6 mutation • MSH2 mutation • MLH1 mutation